Generic Portfolio (Complex Generics)
Not Applicable (Generic)
Pre-ANDAActive
Key Facts
About 6S Pharma
6S Pharma is an early-stage, private biotech startup employing a dual-strategy business model centered on 505(b)(2) drug repurposing and complex generic development. The company is preparing to file IND applications for two of its 505(b)(2) products and advance them into human proof-of-concept studies, while also planning ANDA filings for complex generics by the end of 2024. With a pipeline targeting indications with substantial market opportunities (each exceeding $2 billion) and an experienced leadership team with FDA and global development expertise, 6S aims to create a dynamic portfolio that balances innovation with rapid revenue potential.
View full company profile